Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics

Journal of Psychiatric Research

Volumn 31, Issue 2, 1997, Pages 233-256

  Bachus, Susan E ^a   Hyde, Thomas M ^a   Herman, Mary M ^a   Egan, Michael F ^a   Kleinman, Joel E ^a  

^a St Elizabeths Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; MESSENGER RNA;

ADULT; AGED; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; HIPPOCAMPUS; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERNEURON; MALE; NEUROPATHOLOGY; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBICULUM;

EID: 0030854546     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(96)00041-6     Document Type: Article

References (166)

1. Adams, C. E., & Fisher, R. S. (1990). Sources of neostriatal cholecystokinin in the cat. J Comp Neural, 292, 563-574.
2. Akaike, A., Tamura, Y., Sato, Y., Ozaki, K., Matsuoka, R., Miura, S., & Yoshinaga, T. (1991). Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity. Brain Res, 557, 303-307.
3. Akbarian, S., Bunney, W. E. Jr, Potkin, S. G., Wigal, S. B., Hagman, J. O., Sandman, C. A., & Jones, E. G. (1993a). Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry, 50, 169-177.
4. Akbarian, S., Vinuela, A., Kim, J. J., Potkin, S. G., Bunney, W. E. Jr, & Jones, E. G. (1993b). Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry, 50, 178-187.
5. Akbarian, S., Kim, J. J., Potkin, S. G., Hagman, J. O., Tafazzoli, A., Bunney, W. E. Jr, & Jones, E. G. (1995). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry, 52, 258-266.
6. Albus, M., Ackenheil, M., Munch, U., & Naber, D. (1984). Ceruletide: a new drug for the treatment of schizophrenic patients? Arch Gen Psychiatry, 41, 528.
7. Albus, M., von Gellhorn, K., Munch, U., Naber, D., & Ackenheil, M. (1986). A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results. Psychiatry Res, 19, 1-7.
8. Altshuler, L. L., Casanova, M. F., Goldberg, T. E., & Kleinman, J. E. (1990). The hippocampus and parahippocampus in schizophrenic, suicide, and control brains. Arch Gen Psychiatry, 47, 1029-1034.
9. Arango, V., Underwood, M. D., Gubbi, A. V., & Mann, J. J. (1995). Localized alterations in pre-and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res, 688, 121-133.
10. Arnold, S. E., Lee, V.M.-Y., Gur, R. E., & Trojanowski, J. Q. (1991). Abnormal expression of two microtubule-associated proteins (MAP-2 and MAP-5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci U.S.A., 88, 10850-10854.
11. Baleydier, C., & Mauguière, F. (1980). The duality of the cingulate gyrus in monkey: neuroanatomical study and functional hypothesis. Brain, 103, 525-554.
12. Benes, F. M., Davidson, J., & Bird, E. D. (1986). Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry, 43, 31-35.
13. Benes, F. M., Sorensen, I., Vincent, S. L., Bird, E. D., & Sathi, M. (1992). Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb Cortex, 2, 503-512.
14. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci, 12, 924-929.
15. Blackstad, T. W. (1956). Commissural connections of the hippocampal region in the rat, with special reference to their mode of termination. J Comp Neural, 105, 417-537.
16. Bloom, D. M., Nair, N. P. V., & Schwartz, G. (1983). CCK-8 in the treatment of chronic schizophrenia. Psychopharmacol Bull, 19, 361-363.
17. Bogerts, B. (1984). Zur Neuropathologie der Schizophrenien. Fortschr Neurol Psychiatr, 52, 428-437.
18. Bogerts, B. (1989). Limbic & paralimbic pathology in schizophrenia: interaction with age-and stress-related factors. In S. C. Schulz & C. A. Tamminga, (Eds), Schizophrenia: Scientific Progress (pp. 216-226). New York: Oxford University Press.
19. Bogerts, B., Meertz, E., & Schönfeldt-Bausch, R. (1985). Basal ganglia and limbic system pathology in schizophrenia: a morphometric study of brain volume and shrinkage. Arch Gen Psychiatry, 42, 784-791.
20. Bogerts, B., Falkai, P., Haupts, M., Greve, B., Ernst, S., Tapernon-Franz, U., & Heinzmann, U. (1990). Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics: initial results from a new brain collection. Schizophr Res, 3, 295-301.
21. Boza, R. A., & Rotondo, D. J. (1985). Is cholecystokinin therapeutic in chronic schizophrenia? J Clin Psychiatry, 46, 485-486.
22. Brown, R., Colter, N., Corsellis, J. A. N., Crow, T. J., Frith, C. D., Jagoe, R., Johnstone, E. C., & Marsh, L. (1986). Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry, 43, 36-42.
23. Burgunder, J.-M., & Young, W. S. III (1990). Cortical neurons expressing the cholecystokinin gene in the rat: distribution in the adult brain, ontogeny, and some of their projections. J Comp Neural, 300, 26-46.
24. Casanova, M. F., Goldberg, T. E., Suddath, R. L., Daniel, D. G., Rawlings, R., Lloyd, D. G., Loats, H. L., Kleinman, J. E., & Weinberger, D. R. (1990). Quantitative shape analysis of the temporal and prefrontal lobes of schizophrenic patients: a magnetic resonance image study. J Neuropsychiatry Clin Neurosci, 2, 363-372.
25. Chang, R. S. L., & Lotti, V. J. (1986). Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci U.S.A., 83, 4923-4926.
26. Chesselet, M.-F., Weiss, L., Wuenschell, C., Tobin, A. J., & Affolter, H.-U. (1987). Comparative distribution of mRNAs for glutamic acid decarboxylase, tyrosine hydroxylase, and tachykinins in the basal ganglia: an in situ hybridization study in the rodent brain. J Comp Neural, 262, 125-140.
27. Chiodo, L. A., & Bunney, B. S. (1983). Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system. Science, 219, 1449-1451.
28. 3H]GABA. Neuroscience, 22, 425-439.
29. Chun, J. J. M., Nakamura, M. J., & Shatz, C. J. (1987). Transient cells of the developing mammalian telencephalon are peptide-immunoreactive neurons. Nature, 325, 617-620.
30. Colter, N., Battal, S., Crow, T. J., Johnstone, E. C., Brown, R., & Bruton, C. (1987). White matter reduction in the parahippocampal gyrus of patients with schizophrenia. Arch Gen Psychiatry, 44, 1023.
31. Cottingham, S. L., Pickar, D., Shimotake, T. K., Montpied, P., Paul, S. M., & Crawley, J. N. (1990). Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration. Cell Mol Neurobiol, 10, 41-50.
32. Davidson, M., Haroutunian, V., Gabriel, S. M., Powchik, P., Harvey, P. D., Mohs, R. C., & Davis, K. L. (1994). Cognitive impairment in elderly schizophrenic patients. Schizophr Res, 11, 162-163.
33. Deakin, J. F. W., Slater, P., Simpson, M. D. C., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., & Cross, A. J. (1989). Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem, 52, 1781-1786.
34. Delfs, J. R., & Dichter, M. A. (1985). Cholecystokinin-octapeptide enhances synaptic activity in neurons cultured from rat cerebral cortex. Peptides, 6 (Suppl. 1), 139-144.
35. DeLisi, L. E., Dauphinais, I. D., & Gershon, E. S. (1988). Perinatal complications and reduced size of brain limbic structures in familial schizophrenia. Schizophr Bull, 14, 185-191.
36. Deschenes, R. J., Lorenz, L. J., Haun, R. S., Roos, B. A., Collier, K. J., & Dixon, J. E. (1984). Cloning and sequence analysis of a cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci U.S.A., 81, 726-730.
37. Deschodt-Lanckman, M., & Bui, N. D. (1981) Cholecystokinin octa-and tetrapeptide degradation by synaptic membranes. I. evidence for competition with enkephalins for in vitro common degradation pathways. Peptides, 2(Suppl. 2), 113-118.
38. Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., & Morihisa, J. M. (1989). A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol, 12, 1-13.
39. Dodd, J., & Kelly, J. S. (1981). The actions of cholecystokinin and related peptides on pyramidal neurones of the mammalian hippocampus. Brain Res, 205, 337-350.
40. Eastwood, S. L., McDonald, B., Burnet, P. W. J., Beckwith, J. P., Kerwin, R. W., & Harrison, P. J. (1995). Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Molecular Brain Research, 29, 211-223.
41. Egan, M. F., Hurd, Y., Hyde, T. M., Weinberger, D. R., Wyatt, R. J., & Kleinman, J. E. (1994). Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigral and striatopallidal neurons of rats with neuroleptic-induced dyskinesias. Synapse, 18, 178-189.
42. Fagg, G. E., & Foster, A. C. (1983). Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience, 9, 701-719.
43. Falkai, P., & Bogerts, B. (1986). Cell loss in the hippocampus of schizophrenics. European Archives of Psychiatry and Neurological Sciences, 236, 154-161.
44. Falkai, P., Bogerts, B., & Rozumek, M. (1988). Limbic pathology in schizophrenia: the entorhinal region - a morphometric study. Biol Psychiatry, 24, 515-521.
45. Farmery, S. M., Owen, F., Poulter, M., & Crow, T. J. (1985). Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci, 36, 473-477.
46. Ferrier, I. N., Roberts, G. W., Crow, T. J., Johnstone, E. C., Owens, D. G. C., Lee, Y. C., O'Shaughnessy, D., Adrian, T. E., Polak, J. M., & Bloom, S. R. (1983). Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci, 33, 475-482.
47. Ferrier, I. N., Crow, T. J., Farmery, S. M., Roberts, G. W., Owen, F., Adrian, T. E., & Bloom, S. R. (1985). Reduced cholecystokinin levels in the limbic lobe in schizophrenia: a marker for pathology underlying the defect state? Ann NY Acad Sci, 448, 495-506.
48. Fey, E. T. (1951). The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. J Consult Psychol, 15, 311-319.
49. Fredens, K., Stengaard-Pedersen, K., & Larsson, L.-I. (1984). Localization of enkephalin and cholecystokinin immunoreactivities in the perforant path terminal fields of the rat hippocampal formation. Brain Res, 304, 255-263.
50. Frey, P. (1983). Cholecystokinin octapeptide levels in rat brain are changed after subchronic neuroleptic treatment. Eur J Pharmacol, 95, 87-92.
51. Friston, K. J., Liddle, P. F., Frith, C. D., Hirsch, S. R., & Frackowiak, R. S. J. (1992). The left medial temporal region and schizophrenia: a PET study. Brain, 115, 367-382.
52. Frohna, P. A., Neal-Beliveau, B. S., & Joyce, J. N. (1993). Neonatal 6-OHDA lesions upregulate adult expression of tyrosine hydroxylase mRNA. Neuroreport, 4, 1095-1098.
53. Garey, L. J., Ong, W. Y., Patel, T. S., Kanani, M., Davis, A., Hornstein, C., & Bauer, M. (1995). Reduction in dendritic spine number on cortical pyramidal neurons in schizophrenia. Society for Neuroscience Abstracts, 21, 237.
54. Glantz, L. A., & Lewis, D. A. (1995). Assessment of spine density on layer III pyramidal cells in the prefrontal cortex of schizophrenic subjects. Society for Neuroscience Abstracts, 21, 239.
55. Goldman-Rakic, P. S., Selemon, L. D., & Schwartz, M. L. (1984). Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey. Neuroscience, 12, 719-743.
56. Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991). The neuropsychology of schizophrenia. Behavioral and Brain Sciences, 14, 1-84.
57. Greenwood, R. S., Godar, S. E., Reaves, T. A. Jr, & Hayward, J. N. (1981). Cholecystokinin in hippocampal pathways. J Comp Neurol 203, 335-350.
58. Gysling, K., & Beinfeld, M. C. (1984). Failure of chronic haloperidol treatment to alter levels of cholecystokinin in the rat brain striatum and olfactory tubercle-nucleus accumbens area. Neuropeptides, 4, 421-423.
59. 3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci, 40, 259-266.
60. Harrison, P. J., McLaughlin, D., & Kerwin, R. W. (1991). Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, 337, 450-452.
61. Hays, S. E., Meyer, D. K., & Paul, S. M. (1981). Localization of cholecystokinin receptors on neuronal elements in rat caudate nucleus. Brain Res, 219, 208-213.
62. Hendry, S. H. C., Jones, E. G., DeFelipe, J., Schmechel, D., Brandon, D., & Emson, P. C. (1984). Neuropeptide-containing neurons of the cerebral cortex are also GABAergic. Proc Natl Acad Sci U.S.A., 81, 6526-6530.
63. Hökfelt, T., Ljungdahl, Å., Fuxe, K., & Johansson, O. (1974). Dopamine nerve terminals in the rat limbic cortex: aspects of the dopamine hypothesis of schizophrenia. Science, 184, 177-179.
64. Hökfelt, T., Skirboll, L., Rehfeld, J. F., Goldstein, M., Markey, K., & Dann, O. (1980). A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing. Neuroscience, 5, 2093-2124.
65. Hommer, D. W., Pickar, D., Roy, A., Ninan, P., Boronow, J., & Paul, S. M. (1984). The effects of ceruletide in schizophrenia. Arch Gen Psychiat, 41, 617-619.
66. Hughes, J., Boden, P., Costall, B., Domeney, A., Kelly, E., Horwell, D. C., Hunter, J. C., Pinnock, R. D., & Woodruff, G. N. (1990). Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U.S.A., 87, 6728-6732.
67. Hyde, T. M., & Weinberger, D. R. (1990). The brain in schizophrenia. Semin Neurol, 10, 276-286.
68. Insausti, R., Amaral, D. G., & Cowan, W. M. (1987a). The entorhinal cortex of the monkey: II cortical afferents. J Comp Neurol, 264, 356-395.
69. Insausti, R., Amaral, D. G., & Cowan, W. M. (1987b). The entorhinal cortex of the monkey: III subcortical afferents. J Comp Neurol, 264, 396-408.
70. Itoh, H., Tanoue, S., Yagi, G., Tateyama, M., Kamisada, M., Fujii, Y., Takamiya, M., & Nakajima, S. (1982). Clinical study on the psychotropic effects of Caerulein - an open clinical trial in chronic schizophrenic patients. Keio J Med, 31, 71-95.
71. Itoh, H., Shimazono, Y., Kawakita, Y., Kudo, Y., Satoh, Y., & Takahashi, R. (1986). Clinical evaluation of ceruletide in schizophrenia: a multi-institutional cooperative double-blind controlled study. Psvchopharmacol Bull, 22, 123-128.
72. Jakob, H., & Beckmann, H. (1986). Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm, 65, 303-326.
73. Jenkins, P. L. (1984). Is cholecystokinin an antipsychotic agent? J Clin Psychiatry, 45, 317.
74. Jones, R. S. G. (1993). Entorhinal-hippocampal connections: a speculative view of their function. Trends Neurosci, 16, 58-64.
75. Jones, E. G., & Hendry, S. H. C. (1986). Co-localization of GABA and neuropeptides in neocortical neurons. Trends Neurosci, 9, 71-76.
76. Kádár, T., Fekete, M., & Telegdy, G. (1981). Modulation of passive avoidance behaviour of rats by intracerebroventricular administration of cholecystokinin octapeptide sulfate ester and nonsulfated cholecystokinin octapeptide. Acta Physiol Acad Sci Hung, 58, 269-274.
77. Kawasaki, Y., Maeda, Y., Suzuki, M., Urata, K., Higashima, M., Kiba, K., Yamaguchi, N., Matsuda, H., & Hisada, K. (1993). SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr Res, 10, 109-116.
78. Kerwin, R., Patel, S., & Meldrum, B. (1990). Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 39, 25-32.
79. Kerwin, R., Robinson, P., & Stephenson, J. (1992). Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: A post-mortem autoradiographic study. Psychol Med, 22, 37-43.
80. Kiuchi, Y., Kobayashi, T., Takeuchi, J., Shimizu, H., Ogata, H., & Toru, M. (1989). Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychiatry Neurol Sci, 239, 71-78.
81. Kleinman, J. E., Iadarola, M., Govoni, S., Hong, J., Gillin, J. C., & Wyatt, R. J. (1983). Postmortem measurements of neuropeptides in human brain. Psychopharmacol Bull, 19, 375-377.
82. Köhler, C. (1986). Cytochemical architecture of the entorhmal area. Adv Exp Med Biol, 203, 83-98.
83. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm, 77, 231-236.
84. Kresse, A. E., Reyes, A., Micevych, P., & Maidment, N. T. (1995). The origin of CCK in caudate and nucleus accumbens: combined microdialysis, retrograde tracing and in situ hybridization analyses. Society for Neuroscience Abstracts, 21, 2050.
85. Krimer, L. S., Herman, M. M., Saunders, R. C., Boyd, J. C., Kleinman, J. E., Hyde, T. M., & Weinberger, D. R. (1995). Qualitative and quantitative analysis of the entorhinal cortex cytoarchitectural organization in schizophrenia. Society for Neuroscience Abstracts, 21, 239.
86. Ladurelle, N., Durieux, C., Roques, B. P., & Daugé, V. (1994). Different modifications of the dopamine metabolism in the core and shell parts of the nucleus accumbens following CCK-A receptor stimulation in the shell region. Neurosci Lett, 178, 5-10.
87. 2)-receptor-binding sites: effects of neuronal lesions. Adv Biochem Psychopharmacol, 37, 373-383.
88. Liang, R. Z., Wu, M., Yim, C. C. Y., & Mogenson, G. J. (1991). Effects of dopamine agonists on excitatory inputs to nucleus accumbens neurons from the amygdala: modulatory actions of cholecystokinin. Brain Res, 554, 85-94.
89. Lorente de Nó, R. (1933). Studies on the structure of the cerebral cortex. Journal Für Psychologie Und Neurologie, 45, 381-438.
90. Lotstra, F., Verbanck, P., Mendlewicz, J., & Vanderhaeghen, J. J. (1984). No evidence of antipsychotic effect of caerulein in schizophrenic patients free of neuroleptics: a double-blind cross-over study. Biol Psychiatry, 19, 877-882.
91. 2 and β-adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry, 43, 954-959.
92. Marshall, F. H., Barnes, S., Hughes, J., Woodruff, G. N., & Hunter, J. C. (1991). Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. J Neurochem, 56, 917-922.
93. Matsunaga, T., Shimada, A., Mukhin, A. G., Ingram, D. K., Zukin, S. R., Kleinman, J., Casanova, M., & London, E. D. (1995). NMDA receptor domains in postmortem brains of schizophrenic patients. Society for Neuroscience Abstracts, 21, 2125.
94. Mattes, J. A., Horn, W., & Rochford, J. M. (1985). A high-dose, double-blind study of ceruletide in the treatment of schizophrenia. Am J Psychiatry, 142, 1482-1484.
95. McGeer, P. L., McGeer, E. G., Scherer, U., & Singh, K. (1977). A glutamatergic corticostriatal path? Brain Res, 128, 369-373.
96. Meyer, D. K., Beinfeld, M. C., & Brownstein, M. J. (1982a). Corpus callosum lesions increase cholecystokinin concentrations in cortical areas with homeotopic connections. Brain Res, 240, 151-153.
97. Meyer, D. K., Beinfeld, M. C., Oertel, W. H., & Brownstein, M. J. (1982b). Origin of the cholecystokinin-containing fibers in the rat caudatoputamen. Science, 215, 187-188.
98. 14C-plastic standards for quantitative autoradiography using LKB Ultrofilm or Amersham Hyperfilm. Neurosci Lett, 121, 211-214.
99. Moroji, T., Watanabe, N., & Aoki, N., Itoh, S. (1982). Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia. Int Pharmacopsychiat, 17, 255-273.
100. Nair, N. P. V., Bloom, D. M., Debonnel, G., Schwartz, G., & Mosticyan, S. (1984). Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study. Prog Neuropsvchopharmacol Biol Psychiatry, 8, 711-714.
101. Nair, N. P. V., Bloom, D. M., & Nestoros, J. N. (1982). Cholecystokinin appears to have antipsychotic properties. Prog Neuropsvchopharmacol Biol Psychiatry, 6, 509-512.
102. Newman, R., & Winans, S. S. (1980). An experimental study of the ventral striatum of the golden hamster. I. neuronal connections of the nucleus accumbens. J Comp Neurol, 191, 167-192.
103. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett, 40, 245-250.
104. Noga, J. T., Hyde, T. M., Spurney, C. F., Herman, M., Bigelow, L., Weinberger, D. R. & Kleinman, J. E. (1994). Glutamate receptor and uptake sites in entorhinal cortex in schizophrenia and controls. American College of Neuropsychopharmacology Abstracts 33rd Annual Meeting, p. 220.
105. O'Donnell, P., & Grace, A. A. (1995). Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci, 15, 3622-3639.
106. Oeth, K. M., & Lewis, D. A. (1992). Cholecystokinin-and dopamine-containing mesencephalic neurons provide distinct projections to monkey prefrontal cortex. Neurosci Lett, 145, 87-92.
107. Oeth, K. M., & Lewis, D. A. (1993). Postnatal development of the Cholecystokinin innervation of monkey prefrontal cortex. J Comp Neurol, 336, 400-418.
108. Okada, F., Crow, T. J., & Roberts, G. W. (1991). G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J Neural Transm Gen Sect, 84, 147-153.
109. Olney, J. W., & Farber, N. B. (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry, 52, 998-1007.
110. Palacios, J. M., Savasta, M., & Mengod, G. (1989). Does Cholecystokinin colocalize with dopamine in the human substantia nigra? Brain Res, 488, 369-375.
111. Passaro, E. Jr, Debas, H., Oldendorf, W., & Yamada, T. (1982). Rapid appearance of intraventricularly administered neuropeptides in the peripheral circulation. Brain Res, 241, 335-340.
112. Perry, R. H., Dockray, G. J., Dimaline, R., Perry, E. K., Blessed, G., & Tomlinson, B. E. (1981). Neuropeptides in Alzheimer's disease, depression and schizophrenia: a post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex. J Neurol Sci, 51, 465-472.
113. Peselow, E., Angrist, B., Sudilovsky, A., Corwin, J., Siekierski, J., Trent, F., & Rotrosen, J. (1987). Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia. Psvchopharmacology, 91, 80-84.
114. Radke, J. M., MacLennan, A. J., Beinfeld, M. C., Bissette, G., Nemeroff, C. B., Vincent, S. R., & Fibiger, H. C. (1989). Effects of short-and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. Brain Res, 480, 178-183.
115. Rance, N. E., & Young, W. S. III (1991). Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women. Endocrinology, 128, 2239-2247.
116. Reynolds, G. P., Czudek, C., & Andrews, H. B. (1990). Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry, 27, 1038-1044.
117. Roberts, G. W. (1990) Brain development and CCK systems in schizophrenia: a working hypothesis. In M. P. I. Weller (Ed.), International Perspectives in Schizophrenia: Biological, Social and Epidemiological Findings (pp. 51-69). London: J. Libbey.
118. Rosene, D. L., & Van Hoesen, G. W. (1977). Hippocampal efferents reach widespread areas of cerebral cortex and amygdala in the rhesus monkey. Science, 198, 315-317.
119. Saunders, R. C., & Rosene, D. L. (1988). A comparison of the efferents of the amygdala and the hippocampal formation in the rhesus monkey: I. convergence in the entorhinal, prorhinal, and perirhinal cortices. J Comp Neurol, 271, 153-184.
120. Schalling, M., Friberg, K., Seroogy, K., Riederer, P., Bird, E., Schiffmann, S. N., Mailleux, P., Vanderhaeghen, J.-J., Kuga, S., Goldstein, M., Kitahama, K., Luppi, P. H., Jouvet, M., & Hökfelt, T. (1990). Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci U.S.A., 87, 8427-8431.
121. Selemon, L. D., & Goldman-Rakic, P. S. (1985). Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci, 5, 776-794.
122. Selemon, L. D., & Goldman-Rakic, P. S. (1988). Common cortical and subcortical targets of the dorsolateral prefrontal and posterior parietal cortices in the rhesus monkey: evidence for a distributed neural network subserving spatially guided behavior. J Neurosci, 8, 4049-4068.
123. Seroogy, K., Schalling, M., Brené, S., Dagerlind, Å, Chai, S. Y., Hökfelt, T., Persson, H., Brownstein, M., Huan, R., Dixon, J., Filer, D., Schlessinger, D., & Goldstein, M. (1989). Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry. Exp Brain Res, 74, 149-162.
124. 2 receptors in interneurons. Synapse, 9, 208-218.
125. Sherman, A. D., Davidson, A. T., Baruah, S., Hegwood, T. S., & Waziri, R. (1991a). Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett, 121, 77-80.
126. Sherman, A. D., Hegwood, T. S., Baruah, S., & Waziri, R. (1991b). Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry, 30, 1191-1198.
127. Simpson, M. D. C., Slater, P., Deakin, J. F. W., Royston, M. C., & Skan, W. J. (1989). Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett, 107, 211-215.
128. Sirinathsinghji, D. J. S., Kupsch, A., Mayer, E., Zivin, M., Pufal, D., & Oertel, W. H. (1992). Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Molecular Brain Research, 12, 267-274.
129. Somogyi, P., Hodgson, A. J., Smith, A. D., Nunzi, M. G., Gorio, A., & Wu, J.-Y. (1984). Different populations of GABAergic neurons in the visual cortex and hippocampus of cat contain somatostatin-or cholecystokinin-immunoreactive material. J Neurosci, 4, 2590-2603.
130. Sørensen, K. E., & Witter, M. P. (1983). Entorhinal efferents reach the caudato-putamen. Neurosci Lett, 35, 259-264.
131. 3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res, 2, 219-223.
132. Storm-Mathisen, J. (1977). Glutamic acid and excitatory nerve endings: reduction of glutamic acid uptake after axotomy. Brain Res, 120, 379-386.
133. 3H]glutamic acid in excitatory nerve endings: light and electronmicroscopic observations in the hippocampal formation of the rat. Neuroscience, 4, 1237-1253.
134. Studler, J. M., Reibaud, M., Tramu, G., Blanc, G., Glowinksi, J., & Tassin, J. P. (1985). Distinct properties of cholecystokinin-8 and mixed dopamine-cholecystokinin-8 neurons innervating the nucleus accumbens. Ann NY Acad Sci, 448, 306-314.
135. Studler, J. M., Reibaud, M., Hervé, D., Blanc, G., Glowinski, J., & Tassin, J. P. (1986). Opposite effects of sulfated cholecystokinin on DA-sensitive adenylate cyclase in two areas of the rat nucleus accumbens. Eur J Pharmacol, 126, 125-128.
136. Suddath, R. L., Casanova, M. F., Goldberg, T. E., Daniel, D. G., Kelsoe, J. R. Jr, & Weinberger, D. R. (1989). Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am J Psychiatry, 146, 464-472.
137. Suddath, R. L., Christison, G. W., Torrey, E. F., Casanova, M. F., & Weinberger, D. R. (1990). Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med, 322, 789-794.
138. Swanson, L. W., & Köhler, C. (1986). Anatomical evidence for direct projections from the entorhinal area to the entire cortical mantle in the rat. J Neurosci, 6, 3010-3023.
139. Takahashi, T., Arai, H., Inoue, R., Matsumoto, A., Mckenna, P., & Emson, P. C. (1995). Distribution of CCK mRNA in prefrontal cortex of schizophrenics. Society for Neuroscience Abstracts, 21, 2125.
140. Tamminga, C. A., Littman, R. L., & Alphs, L. D. (1986). Cholecystokinin: a neuropeptide in the treatment of schizophrenia. Psychopharmacol Bull, 22, 129-132.
141. Tamura, Y., Sato, Y., Akaike, A., & Shiomi, H. (1992). Mechanisms of cholecystokinin-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res, 592, 317-325.
142. Taxt, T., & Storm-Mathisen, J. (1984). Uptake of D-aspartate and L-glutamate in excitatory axon terminals in hippocampus: autoradiographic and biochemical comparison with γ-aminobutyrate and other amino acids in normal rats and in rats with lesions. Neuroscience, 11, 79-100.
143. Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., & Ogawa, A. (1988). Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand, 78, 121-137.
144. Totterdell, S., & Smith, A. D. (1986). Cholecystokinin-immunoreactive boutons in synaptic contact with hippocampal pyramidal neurons that project to the nucleus accumbens. Neuroscience, 19, 181-192.
145. Totterdell, S., & Smith, A. D. (1989). Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J Chem Neuroanat, 2, 285-298.
146. Tsai, G., Passani, L. A., Slusher, B. S., Carter, R., Baer, L., Kleinman, J. E., & Coyle, J. T. (1995). Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry, 52, 829-836.
147. Van Hoesen, G. W., & Pandya, D. N. (1975). Some connections of the entorhinal (area 28) and perirhinal (area 35) cortices of the rhesus monkey: III. efferent connections. Brain Res, 95, 39-59.
148. van Ree, J. M., Verhoeven, W. M. A., Brouwer, G. J., & de Wied, D. (1984). Ceruletide resembles antipsychotics in rats and schizophrenic patients: preliminary report. Neuropsychobiology, 12, 4-8.
149. van Ree, J. M., Verhoeven, W. M. A., & de Wied, D. (1987). Animal and clinical research on neuropeptides and schizophrenia. Prog Brain Res, 72, 249-267.
150. 3H]dopamine efflux from rat nucleus accumbens. Neuropeptides, 13, 43-50.
151. A and benzodiazepine receptor binding in the hippocampal formation of schizophrenics. Society for Neuroscience Abstracts, 21, 2127.
152. Virgo, L., Humphries, C., Mortimer, A., Barnes, T., Hirsch, S., & de Belleroche, J. (1995). Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry, 37, 694-701.
153. Vogt, B. A., Nimchinsky, E. A., Vogt, L. J., & Hof, P. R. (1995). Human cingulate cortex: surface features, flat maps, and cytoarchitecture. J Comp Neurol, 359, 490-506.
154. Walaas, I., & Fonnum, F. (1979). The effects of surgical and chemical lesions on neurotransmitter candidates in the nucleus accumbens of the rat. Neuroscience, 4, 209-216.
155. Wang, R. Y., & Hu, X.-T. (1986). Does cholecystokinin potentiate dopamine action in the nucleus accumbens? Brain Res, 380, 363-367.
156. Weinberger, D. R. (1991) Anteromedial temporal-prefrontal connectivity: a functional neuroanatomical system implicated in schizophrenia. In B. J. Carroll & J. E. Barrett (Eds), Psychopathology and the Brain (pp. 25-43). New York: Raven Press.
157. Weinberger, D. R., & Lipska, B. K. (1995). Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res, 16, 87-110.
158. Weinberger, D. R., Berman, K. F., & Zee, R. F. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. regional cerebral blood flow evidence. Arch Gen Psychiatry, 43, 114-124.
159. Weinberger, D. R., Berman, K. F., Suddath, R., & Torrey, E. F. (1992), Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry, 149, 890-897.
160. White, F. J., & Wang, R. Y. (1984). Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Brain Res, 300, 161-166.
161. Wolf, S. S., Hyde, T. M., Saunders, R. C., Herman, M. M., Weinberger, D. R., & Kleinman, J. E. (1995). Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J Neural Transm Gen Sect, 102, 55-65.
162. Yamagami, S., Hirayama, E., Mori, H., & Kawakita, Y. (1986). Dose-effect relationship of ceruletide in the treatment of neuroleptic-resistant schizophrenia. Therapeutic Research, 39, 1044-1053.
163. Yang, C. R., & Mogenson, G. J. (1984) Electrophysiological responses of neurones in the nucleus accumbens to hippocampal stimulation and the attenuation of the excitatory responses by the mesolimbic dopaminergic system. Brain Res, 324, 69-84.
164. Yeterian, E. H., & Van Hoesen, G. W. (1978). Cortico-striate projections in the rhesus monkey: the organization of certain cortico-caudate connections. Brain Res, 139, 43-63.
165. Yim, C. C., & Mogenson, G. J. (1991). Electrophysiological evidence of modulatory interaction between dopamine and cholecystokinin in the nucleus accumbens. Brain Res, 541, 12-20.
166. Young, W. S., III (1992) In situ hybridization with oligodeoxyribonucleotide probes. In D. G. Wilkinson (Ed.), In Situ Hybridization: A Practical Approach (pp. 33-44). New York: Oxford University Press.